US big biopharma companies reported steady first quarter sales growth, but for several drug makers, sales of COVID-19 vaccines and treatments powered that growth. While the revenue boost is welcomed by investors, uncertainty around the evolving pandemic and the long-term outlook for the franchises means drug makers need to show their core businesses are also on a solid footing.
A mounting overhang for the big pharma sector in general is loss of exclusivities (LOE) for key drugs that are...



![[Test]With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space](https://web.insights.norstella-labs.com/resizer/v2/G3M6E2FVDNOJPCEXELJNOIKH64.jpg?smart=true&auth=b5d5c6477bcbd6c122699f47191cbafe560695783f500a6e7b10c4d270965bdc&width=400&height=225)
